Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus HYTONE.
COR-OTICIN vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
1-2 drops in each affected ear twice daily for 7 days.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid